Rationale and design of the anticoagulant therapy after left atrial appendage closure (ATLAAC) trial.
Kristina Gosvig, Julie Goller, Nils Henrik Hansson...
https://pubmed.ncbi.nlm.nih.gov/40246048/Actively Recruiting
Led by Odense University Hospital · Updated on 2026-10-21
1220
Participants Needed
6
Research Sites
N/A
Total Duration
Researchers are studying patients with atrial fibrillation who have had surgical closure of the left atrial appendage LAA to see if they can safely stop taking oral anticoagulants. This trial addresses the important question of whether anticoagulant therapy is still needed after successful LAA closure, since continuing anticoagulation carries a risk of bleeding. The study is a randomized trial enrolling 1220 patients to evaluate risks of stroke, embolism, and bleeding. Participants will first undergo a cardiac CT scan to confirm the success of their LAA closure. Those with successful closure will be randomly assigned to either stop or continue their oral anticoagulant medications, which include warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban. The trial compares these two groups over approximately four years to assess key health outcomes. During the study, participants will be monitored for ischemic strokes, peripheral arterial embolisms, and major bleeding events. Additional evaluations include the severity of strokes, transient ischemic attacks, mortality rates, minor bleeding, and quality of life assessments at baseline, one year, and two years. The trial aims to provide detailed safety and effectiveness data about continuing versus stopping anticoagulants after surgical LAA closure.
CONDITIONS
Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)
K
Kristina Gosvig, M.D.
J
Julie Goller, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Odense University Hospital
Lead Sponsor
Copenhagen University Hospital, Rigshospitalet
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit including a cardiac CT scan to check left atrial appendage closure success
Duration - Up to 4 years
Participants who qualify are randomly assigned to either stop or continue oral anticoagulant medication for the duration of the study.
Regular follow-up visits to monitor health outcomes
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kristina Gosvig, Julie Goller, Nils Henrik Hansson...
https://pubmed.ncbi.nlm.nih.gov/40246048/Odense University Hospital
Lead Sponsor
Copenhagen University Hospital, Rigshospitalet
Collaborating Sponsor